Combination ovarian test boosts response to therapy
This article was originally published in Clinica
Executive Summary
By combining the actions of two assays, a team at Yale School of Medicine in Connecticut says it could double the response rate of ovarian cancer patients to drug therapy. The exclusive licensee of the new combination assay, Precision Therapeutics, told Clinica that a product could be available by 2007, following the completion of a prospective clinical trial scheduled to begin later this year.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.